AI-assisted research analysis by FutureKnowledge. Sources checked 31 October 2026. This is not investment advice.
Reviewed by FutureKnowledge: figures, dates and attributions were checked against the linked sources before publication.
AstraZeneca’s third-quarter revenue rose 7% to $16.21 billion and core earnings per share reached $2.79, ahead of forecasts, as cancer drugs offset a 25% slide in Farxiga sales. The company also launched a $1.5 billion annual cost-savings programme, and its US-listed shares had their biggest one-day gain in a year.
AstraZeneca Q3 results: the key numbers
In its 9M and Q3 2026 results, published on 30 October, AstraZeneca reported:
- Total revenue: $16,209 million in Q3, up 7% at both actual and constant exchange rates (CER); $46,881 million for the first nine months, up 7% at CER.
- Core EPS: $2.79 in Q3, up 19% at CER; $8.00 for nine months, up 14%.
- Reported EPS: $2.02 in Q3, up 26% at CER.
- Alliance revenue from medicines sold with partners: $1,107 million in Q3, up 36%.
Analysts had expected core EPS of $2.59 and revenue of $15.94 billion, according to a Reuters report carried by Euronext. Investing.com put the core EPS consensus slightly higher at $2.62, and core operating profit of $5.86 billion against a $5.40 billion consensus. On either measure, earnings beat forecasts. Investing.com said lower-than-expected operating costs and $277 million of higher other operating income helped.
Full-year 2026 guidance was reconfirmed: total revenue growth of a mid-to-high single-digit percentage and core EPS growth of a low double-digit percentage, both at CER, with a core tax rate of 18% to 22%.
Why it happened: oncology carries the quarter
Oncology revenue rose 17% to $7.77 billion in the quarter, Reuters reported, and reached $21.9 billion for the nine months, 47% of group revenue, according to the company. Earnings-call highlights carried by Yahoo Finance show Tagrisso topped $2 billion in a quarter for the first time ($2.1 billion, up 12%), Enhertu rose 35% to $969 million and Imfinzi grew 26% to about $2 billion. Rare disease medicines grew 10% to $2.6 billion, led by Ultomiris, Proactive reported.
The weak spot is the older cardiovascular and diabetes franchise. Farxiga sales fell 25% to $1.61 billion after generics arrived; US Farxiga sales fell 71% to $127 million after several generic versions launched in the second quarter, Investing.com reported. The company’s nine-month cardiovascular, renal and metabolism revenue fell 14% at CER. Management said revenue would have grown 12% in the first nine months excluding Farxiga and Brilinta. In China, volume-based procurement continued to weigh on prices.
Not every product beat. Truqap sales of $210 million missed a $254 million forecast, which the company blamed on US destocking, Investing.com said. The quarter also brought pipeline setbacks: Etcamah missed its main goal in the SERENA-4 breast cancer trial, a volrustomig lung cancer trial was stopped and Wainua failed a heart study, Proactive noted.
The $1.5 billion savings plan
AstraZeneca announced a restructuring programme expected to deliver about $1.5 billion of annualised pre-tax savings, with up to $2 billion of one-off costs, largely complete by the end of 2029. Reuters calculated the savings at roughly 4% of 2025 operating expenses of $34.36 billion and said the company gave few details and did not say whether jobs would be cut. Chief financial officer Aradhana Sarin said the savings would be reinvested to support growth, and most of the cost would be cash, according to the call highlights.
The company reaffirmed its 2030 ambition, which Reuters described as $80 billion of annual revenue. Chief executive Pascal Soriot said the company was “on track to deliver our 2030 ambition”. It said late-stage readouts due in 2027 have potential peak-year revenue above $20 billion, before risk adjustment. The company also intends to raise its 2026 dividend to $3.30 a share.
AstraZeneca shares: how the market reacted
Shares rose about 3% in London morning trade, Reuters reported. The US-listed shares closed up 7.02% on a day when the S&P 500 fell 1.82%, according to the Capp Notes market wrap. MoneyCheck said it was the stock’s biggest one-day gain since October 2025 and erased its small loss for the year.
The results land in a mixed season for large drugmakers. Eli Lilly’s Q3 revenue rose 39%, while Novartis raised its 2026 outlook after an 11% rise in core profit. AstraZeneca’s growth is slower but relies on a broader cancer portfolio rather than one class of medicines.
Who is more or less exposed
- Partners in oncology: companies that share revenue on co-marketed drugs, such as Daiichi Sankyo on Enhertu, are tied to these sales trends.
- Generic makers: the Farxiga decline shows how quickly sales can move to generics once exclusivity ends, a pattern that also matters for generic exporters, including Indian firms, though the company did not name them.
- Suppliers and staff: the restructuring’s effect on jobs and contractors is not yet clear, since no breakdown was given.
Scenarios to watch
The table sets out conditional scenarios, not predictions.
| If… | Then, conditionally… |
|---|---|
| Oncology keeps growing in the high teens | Group growth could stay within guidance despite further generic pressure on Farxiga and Brilinta |
| 2027 Phase III readouts are largely positive | The $80 billion 2030 ambition would look better supported |
| More late-stage setbacks follow SERENA-4 and Wainua | Investors may focus more on cost savings than on pipeline value |
| US pricing pressure rises, including Calquence entering IRA pricing in 2027 | Margins could come under strain even with the savings programme |
What to watch next
- Full-year results and 2027 guidance in February; management said it will not give 2027 guidance before then.
- Details on how the restructuring will be carried out, including any effect on jobs.
- The appeal of a Delaware court judgment of $392 million over the Syntimmune acquisition, which Proactive reported.
- China sales once volume-based procurement effects ease.
Bottom line
AstraZeneca’s quarter showed that its cancer medicines can absorb a sharp loss of exclusivity on Farxiga, while the $1.5 billion savings plan gives it more room to fund its pipeline. The reconfirmed guidance and an earnings beat lifted the shares, but the 2030 targets still depend on how the 2027 trial readouts turn out.
Method note: This analysis is based on AstraZeneca’s 9M and Q3 2026 results announcement as the primary source, compared with reporting from Reuters (via Euronext), Investing.com, Proactive and earnings-call highlights (via Yahoo Finance), MoneyCheck and the Capp Notes market wrap. Where sources differed on analyst consensus for core EPS ($2.59 versus $2.62) and on the share move (about 3% in London morning trade versus 7% for the US listing at the close), we have shown both.